Literature DB >> 17311076

[11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects.

Mark Slifstein1, Lawrence S Kegeles, Robyn Gonzales, William G Frankle, Xiaoyan Xu, Marc Laruelle, Anissa Abi-Dargham.   

Abstract

The dopamine D(1) receptor antagonist radioligand [(11)C]NNC 112 has previously been reported to have 100-fold selectivity for the D(1) receptor compared with the serotonin 5-HT(2A) receptor. In this study, we tested the selectivity by scanning seven healthy human research volunteers with [(11)C]NNC 112 before and after 2 mg of the antipsychotic drug risperidone, a dose that putatively blocks all 5-HT(2A) receptors with negligible effect on D(1) receptors. We found that specific binding in cortical regions was reduced by 20% to 30%, whereas the striatum showed no change. Based on the known relative densities of these receptors in humans, our results suggest 5- to 10-fold selectivity of [(11)C]NNC 112 for D(1) versus 5-HT(2A) as opposed to 100-fold selectivity. These results suggest caution in interpreting data from studies using this tracer to measure cortical D(1) receptors as well as the need for more selective radioligands to assess cortical D(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311076     DOI: 10.1038/sj.jcbfm.9600468

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  21 in total

1.  Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects.

Authors:  Chelsea L Robertson; Kenji Ishibashi; Mark A Mandelkern; Amira K Brown; Dara G Ghahremani; Fred Sabb; Robert Bilder; Tyrone Cannon; Jacqueline Borg; Edythe D London
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 2.  Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.

Authors:  Haifeng Hou; Chunyan Wang; Shaowei Jia; Shu Hu; Mei Tian
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

3.  In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia.

Authors:  Eline M P Poels; Ragy R Girgis; Judy L Thompson; Mark Slifstein; Anissa Abi-Dargham
Journal:  Psychopharmacology (Berl)       Date:  2013-03-05       Impact factor: 4.530

4.  Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users.

Authors:  Scott J Moeller; Kyoji Okita; Chelsea L Robertson; Michael E Ballard; Anna B Konova; Rita Z Goldstein; Mark A Mandelkern; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2017-06-30       Impact factor: 7.853

5.  Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.

Authors:  Mark Slifstein; Raymond F Suckow; Jonathan A Javitch; Thomas Cooper; Jeffrey Lieberman; Anissa Abi-Dargham
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

Review 6.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

7.  Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors.

Authors:  Ana M Catafau; Graham E Searle; Santiago Bullich; Roger N Gunn; Eugenii A Rabiner; Raul Herance; Joaquim Radua; Magi Farre; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-23       Impact factor: 6.200

8.  Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

Authors:  Judy L Thompson; Daniel R Rosell; Mark Slifstein; Ragy R Girgis; Xiaoyan Xu; Yosefa Ehrlich; Lawrence S Kegeles; Erin A Hazlett; Anissa Abi-Dargham; Larry J Siever
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

9.  COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo.

Authors:  Mika M Hirvonen; Kjell Någren; Juha O Rinne; Ullamari Pesonen; Tero Vahlberg; Nora Hagelberg; Jarmo Hietala
Journal:  Mol Imaging Biol       Date:  2009-10-01       Impact factor: 3.488

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.